Baseline characteristics of enrolled participants.
diarrhea, abdominal pain, swelling, TEAEs, pain, headache, Scrotal pain
ADVERSE EVENTS
Eighty-seven of 164 (53%) participants experienced at least 1 TEAE in the seven days post-treatment, including 54% of participants in the IA arm, 60% in MoxA, 44% in IDA and 55% in MoxDA arms (p = 0.530). About one third of participants experienced more than one TEAE; 41%, 32%, 34% and 35% for IA, MoxA, IDA and MoxDA, respectively (p = 0.848). The mean number of TEAEs among those with any TEAE were 3.0, 2.0, 2.9, and 2.6 after IA, MoxA, IDA, or MoxDA, respectively (p = 0.197). There were no serious adverse events in any of the treatment arms. There was no difference in baseline characteristics between those who experienced TEAEs and those who did not (Among those experiencing subjective AEs, muscle or joint pain, headache, abdominal pain and diarrhea were most common. Scrotal pain or lymph node swelling occurred in six persons treated with IDA or MoxDA, but not after treatment with IA or MoxA (Tables 